0 44

Cited 0 times in

Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study

 Keun Sik Hong  ;  Sun Uck Kwon  ;  Jong Ho Park  ;  Jae Kwan Cha  ;  Jin Man Jung  ;  Yong Jae Kim  ;  Kyung Bok Lee  ;  Sung Il Sohn  ;  Yong Seok Lee  ;  Joung Ho Rha  ;  Jee Hyun Kwon  ;  Sang Won Han  ;  Bum Joon Kim  ;  Jaseong Koo  ;  Jay Chol Choi  ;  Sang Min Sung  ;  Soo Joo Lee  ;  Man Seok Park  ;  Seong Hwan Ahn  ;  Oh Young Bang  ;  Yang Ha Hwang  ;  Hyo Suk Nam  ;  Jong Moo Park  ;  Hee Joon Bae  ;  Eung Gyu Kim  ;  Kyung Yul Lee  ;  Mi Sun Oh 
 JOURNAL OF CLINICAL NEUROLOGY, Vol.17(3) : 344-353, 2021-07 
Journal Title
Issue Date
blood pressure ; fimasartan ; prevention and control ; stroke
Background and purpose: Blood pressure (BP) control is strongly recommended, but BP control rate has not been well studied in patients with stroke. We evaluated the BP control rate with fimasartan-based antihypertensive therapy initiated in patients with recent cerebral ischemia. Methods: This multicenter, prospective, single-arm trial involved 27 centers in South Korea. Key inclusion criteria were recent cerebral ischemia within 90 days and high BP [systolic blood pressure (SBP) >140 mm Hg or diastolic blood pressure (DBP) >90 mm Hg]. BP lowering was initiated with fimasartan. BP management during the follow-up was at the discretion of the responsible investigators. The primary endpoint was the target BP goal achievement rate (<140/90 mm Hg) at 24 weeks. Key secondary endpoints included achieved BP and BP changes at each visit, and clinical events (ClinicalTrials.gov Identifier: NCT03231293). Results: Of 1,035 patients enrolled, 1,026 were included in the safety analysis, and 951 in the efficacy analysis. Their mean age was 64.1 years, 33% were female, the median time interval from onset to enrollment was 10 days, and the baseline SBP and DBP were 162.3±16.0 and 92.2±12.4 mm Hg (mean±SD). During the study period, 55.5% of patients were maintained on fimasartan monotherapy, and 44.5% received antihypertensive therapies other than fimasartan monotherapy at at least one visit. The target BP goal achievement rate at 24-week was 67.3% (48.6% at 4-week and 61.4% at 12-week). The mean BP was 139.0/81.8±18.3/11.7, 133.8/79.2±16.4/11.0, and 132.8/78.5±15.6/10.9 mm Hg at 4-, 12-, and 24-week. The treatment-emergent adverse event rate was 5.4%, including one serious adverse event. Conclusions: Fimasartan-based BP lowering achieved the target BP in two-thirds of patients at 24 weeks, and was generally well tolerated.
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers
Yonsei Authors
Nam, Hyo Suk(남효석) ORCID logo https://orcid.org/0000-0002-4415-3995
Lee, Kyung Yul(이경열) ORCID logo https://orcid.org/0000-0001-5585-7739
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.